NeRRe Therapeutics is a UK based clinical-stage company developing a unique portfolio of neurokinin (NK) -1 receptor antagonists for the treatment of common debilitating conditions caused by neuronal hypersensitivity.Find Out More
We believe that the NK-1 receptor system presents one of the most exciting yet clinically under-exploited neuropeptide target classes, which has huge potential for a broad range of indications to provide truly innovative treatments to meet medical unmet needs.
NeRRe's ambition is to unlock the significant potential of its full pipeline in particular to progress orvepitant to Phase 3 ready. The NeRRe focus is on developing novel treatments to address common, chronic and debilitating conditions that affect millions of people around the world on a daily basis.
In keeping with our ambition for this target class we are keen to explore opportunities to further develop the other high-quality NK-1 receptor antagonists in our pipeline to enable the full therapeutic promise of this neuropeptide receptor system to be realised.
Find Out More
Mary Kerr CEO NeRRe Therapeutics and Managing Director KaNDY Therapeutics will be presenting a case study on the “Demerger of NT-814 to KaNDY Therapeutics, Business Model Innovation and Value Creation; 7TH LSX CEO FORUM , Wednesday 27th June 2018, CMS, Cannon Place, 78 Cannon St, London EC4N 6AF
Click here to read moreread more
KaNDy Therapeutics and NeRRe Therapeutics announce the appointment of Jo Craig as Head of Chemistry Manufacturing and Controls
Stevenage, UK, 21 June 2018 – KaNDy Therapeutics, a UK clinical-stage biotech company, today announces the appointment of Jo Craig as Head of Chemistry Manufacturing and Controls for both KaNDy Therapeutics and NeRRe Therapeutics, its sister company. Jo Craig joins from GlaxoSmithKline where she was most recently VP of Technology & Strategy, Product Development &…